Skip to main content

Parnate Side Effects

Generic name: tranylcypromine

Medically reviewed by Drugs.com. Last updated on Oct 31, 2023.

Note: This document contains side effect information about tranylcypromine. Some dosage forms listed on this page may not apply to the brand name Parnate.

Applies to tranylcypromine: oral tablet.

Warning

Oral route (Tablet)

Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. Tranylcypromine sulfate is not approved for use in pediatric patients.Excessive consumption of foods or beverages with significant tyramine content or the use of certain drugs with tranylcypromine sulfate or after tranylcypromine sulfate discontinuation can precipitate hypertensive crisis. Monitor blood pressure and allow for medication-free intervals between administration of tranylcypromine sulfate and interacting drugs. Instruct patients to avoid ingestion of foods and beverages with high tyramine content.

Serious side effects of Parnate

Along with its needed effects, tranylcypromine (the active ingredient contained in Parnate) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tranylcypromine:

Incidence not known

Other side effects of Parnate

Some side effects of tranylcypromine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

For Healthcare Professionals

Applies to tranylcypromine: oral tablet.

General

The most important adverse event is hypertensive crisis, which may be fatal. The most common adverse event is insomnia, which can frequently be overcome by giving the last dose of the day no later than 3 pm or reducing dosage.[Ref]

Cardiovascular

Frequency not reported: Edema, flushing, hypertension, hypertensive crisis, hypotension, multiple extrasystoles, pallor, palpitation, postural hypotension/postural hypotension with syncope, severe hypertensive reaction, substernal pain, tachycardia[Ref]

Severe hypertensive reactions have occurred, notably with tyramine containing foods, and are sometimes fatal. Symptoms may include pain and stiffness in the neck, multiple extrasystoles, often with substernal pain, sweating and pallor, sometimes followed by flushing, mydriasis, and photophobia.

Hypotension and postural hypotension were usually temporary, but sometimes required discontinuation of treatment. Blood pressure rapidly returned to pretreatment levels once treatment was stopped.[Ref]

Nervous system

Frequency not reported: Adverse effects on the ability to drive and operate machinery, akathisia, drowsiness, dizziness, dysgeusia, headache, headache without blood pressure elevation, hyperreflexia, lethargy, myoclonic jerks, numbness, nystagmus, paresthesia, sedation, seizures, serotonin syndrome, syncope, throbbing headache, tremor, unusually frequent headaches

Postmarketing reports: Akinesia, ataxia, memory loss[Ref]

Psychiatric

Frequency not reported: Aggravation of coexisting symptoms of depression, agitation, anxiety, discontinuation syndrome, drug dependence, excessive stimulation, hallucinations, hypomania, insomnia, loss of libido, mania, manic symptoms, overexcitement, overstimulation, restlessness, sleep disturbances, suicidal behavior, suicidal ideation/thoughts, withdrawal symptoms

Postmarketing reports: Confusion, disorientation[Ref]

Drug dependence with tolerance to high doses may occur in patients without a history of drug dependence.

Overstimulation included increased anxiety, agitation, and manic symptoms, and was usually a sign of excessive therapeutic action.[Ref]

Gastrointestinal

Frequency not reported: Abdominal pain, constipation, diarrhea, dry mouth, nausea, vomiting

Postmarketing reports: Fissuring in corner of mouth[Ref]

Endocrine

Frequency not reported: Syndrome of inappropriate antidiuretic syndrome (SIADH)[Ref]

Genitourinary

Frequency not reported: Delayed ejaculation, impotence, retarded ejaculation, urinary retention

Postmarketing reports: Urinary frequency, urinary incontinence[Ref]

Hematologic

Frequency not reported: Agranulocytosis, anemia, blood dyscrasias, leukopenia, thrombocytopenia[Ref]

Hepatic

Frequency not reported: Elevated aminotransferases, hepatitis, hepatocellular damage, hepatotoxicity, jaundice[Ref]

Musculoskeletal

Frequency not reported: Muscle spasm, neck stiffness

Postmarketing reports: Localized scleroderma[Ref]

Other

Frequency not reported: Chills, drug tolerance, excessive therapeutic action, fatigue, pain, persistence of MAO inhibition after discontinuation, tinnitus, weakness[Ref]

Ocular

Frequency not reported: Blurred vision, mydriasis, photophobia[Ref]

Dermatologic

Frequency not reported: Alopecia, skin rash/rash, sweating

Postmarketing reports: Flare up of cystic acne, urticaria[Ref]

Metabolic

Frequency not reported: Hypoglycemia, impaired water excretion, significant anorexia, weight gain[Ref]

Frequently asked questions

References

1. Product Information. Parnate (tranylcypromine). SmithKline Beecham. 2001;PROD.

2. Cerner Multum, Inc. UK Summary of Product Characteristics.

3. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer